St. Jude Tries To Get Ahead Of Questions On Durata ICD Leads
This article was originally published in The Gray Sheet
The company hopes an independent analysis of its Optim-insulated Durata leads will address questions from the clinical community based on concerns with its earlier-generation Riata devices.
You may also be interested in...
A 10-year retrospective study from the Cleveland Clinic shows that implantable cardioverter defibrillator leads subject to recalls can be extracted with the same safety and efficacy as non-recalled ICD leads. Another study, published in the same issue of Heart Rhythm, found that younger age and female sex are independent predictors of failure for St. Jude’s Riata lead.
St. Jude launches new ICDs and CRTs with coating to resist lead failures. Meridian earns a 510(k) for a new pneumonia molecular diagnostic. More new product news